发布求助
文献互助 智能选刊 最新文献

World Journal of Hepatology最新文献

筛选
英文 中文
Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease 妊娠糖尿病可能易导致代谢功能障碍相关性脂肪肝
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.860
C. Milionis, Ioannis Ilias, E. Koukkou
{"title":"Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease","authors":"C. Milionis, Ioannis Ilias, E. Koukkou","doi":"10.4254/wjh.v16.i5.860","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.860","url":null,"abstract":"The development of type 2 diabetes mellitus is a major contributing factor to the worldwide health burden of metabolic dysfunction-associated steatotic liver disease (MASLD). Insulin resistance, subclinical inflammation, dyslipidemia, obesity, and hypertension are all factors in this reciprocal interaction that contribute to the development of MASLD, which includes hepatocellular carcinoma, advanced fibrosis/cirrhosis, and non-alcoholic steatohepatitis (NASH). A new risk factor for MASLD/NASH that affects the course of the disease independently throughout life is gestational diabetes mellitus (GDM). Women with a history of GDM had a higher chance of developing NASH, according to a recent study that used a large-scale database. Although the precise etiology is yet unknown, temporary disruption of pancreatic beta cell activity during pregnancy may set off systemic inflammation, affecting distant organs including the liver. Early screening and management strategies are crucial in mitigating MASLD progression and preventing adverse cardiovascular events in affected individuals.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. 胰高血糖素和胰高血糖素受体激动剂在代谢功能障碍相关性脂肪肝中的作用：机遇与挑战。
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.731
Chencheng Xie, Naim Alkhouri, Mohamed A Elfeki
{"title":"Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.","authors":"Chencheng Xie, Naim Alkhouri, Mohamed A Elfeki","doi":"10.4254/wjh.v16.i5.731","DOIUrl":"10.4254/wjh.v16.i5.731","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide, paralleling the rising pandemic of obesity and type 2 diabetes. Due to the growing global health burden and complex pathogenesis of MASLD, a multifaceted and innovative therapeutic approach is needed. Incretin receptor agonists, which were initially developed for diabetes management, have emerged as promising candidates for MASLD treatment. This review describes the pathophysiological mechanisms and action sites of three major classes of incretin/glucagon receptor agonists: glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic polypeptide receptor agonists, and glucagon receptor agonists. Incretins and glucagon directly or indirectly impact various organs, including the liver, brain, pancreas, gastrointestinal tract, and adipose tissue. Thus, these agents significantly improve glycemic control and weight management and mitigate MASLD pathogenesis. Importantly, this study provides a summary of clinical trials analyzing the effectiveness and safety of incretin receptor agonists in MASLD management and provides an in-depth analysis highlighting their beneficial effects on improving liver function, hepatic steatosis, and intrahepatic inflammation. There are emerging challenges associated with the use of these medications in the real world, particularly adverse events, drug-drug interactions, and barriers to access, which are discussed in detail. Additionally, this review highlights the evolving role of incretin receptor agonists in MASLD management and suggests future research directions.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease 揭示组蛋白甲基化与非酒精性脂肪肝之间的关系
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.703
Li Xu, Yu-Hong Fan, Xiao-Jing Zhang, Lan Bai
{"title":"Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease","authors":"Li Xu, Yu-Hong Fan, Xiao-Jing Zhang, Lan Bai","doi":"10.4254/wjh.v16.i5.703","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.703","url":null,"abstract":"Non-alcoholic fatty liver disease (NAFLD) poses a significant health challenge in modern societies due to shifts in lifestyle and dietary habits. Its complexity stems from genetic predisposition, environmental influences, and metabolic factors. Epigenetic processes govern various cellular functions such as transcription, chromatin structure, and cell division. In NAFLD, these epigenetic tendencies, especially the process of histone methylation, are intricately intertwined with fat accumulation in the liver. Histone methylation is regulated by different enzymes like methyltransferases and demethylases and influences the expression of genes related to adipogenesis. While early-stage NAFLD is reversible, its progression to severe stages becomes almost irreversible. Therefore, early detection and intervention in NAFLD are crucial, and understanding the precise role of histone methylation in the early stages of NAFLD could be vital in halting or potentially reversing the progression of this disease.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic pseudotumor: A diagnostic challenge 肝假瘤：诊断难题
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.667
A. Samanta, Moinak Sen Sarma
{"title":"Hepatic pseudotumor: A diagnostic challenge","authors":"A. Samanta, Moinak Sen Sarma","doi":"10.4254/wjh.v16.i5.667","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.667","url":null,"abstract":"Hepatic pseudotumors are rare lesions of unknown origin, characterized by the proliferation of fibrous connective tissue and inflammatory cell infiltrates. They mimic malignant lesions clinically, and radiologically, given their non-specific clinical and imaging features. The pathophysiology of hepatic pseudotumor is incompletely understood and there are no standardized criteria for diagnosis. Pseudotumors have been reported to develop in various organs in the body with the lung and liver being the most common site. Hepatic pseudotumors develop in patients with underlying triggers of liver inflammation and injury, including infections, autoimmune liver diseases, bile duct injury, or surgery. Hepatic pseudotumors respond well to conservative treatment with antibiotics, and steroids and some may regress spontaneously, thus avoiding unnecessary resection. This condition is rewarding to treat. It is important to recognize pseudotumor as a distinct clinical entity and include it in the differential of liver masses with atypical imaging features.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease. 口腔细菌在非酒精性脂肪肝进展过程中的多功能作用。
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.688
En-Hua Mei, Chao Yao, Yi-Nan Chen, Shun-Xue Nan, Sheng-Cai Qi
{"title":"Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease.","authors":"En-Hua Mei, Chao Yao, Yi-Nan Chen, Shun-Xue Nan, Sheng-Cai Qi","doi":"10.4254/wjh.v16.i5.688","DOIUrl":"10.4254/wjh.v16.i5.688","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders of varying severity, ultimately leading to fibrosis. This spectrum primarily consists of NAFL and non-alcoholic steatohepatitis. The pathogenesis of NAFLD is closely associated with disturbances in the gut microbiota and impairment of the intestinal barrier. Non-gut commensal flora, particularly bacteria, play a pivotal role in the progression of NAFLD. Notably, <i>Porphyromonas gingivalis</i>, a principal bacterium involved in periodontitis, is known to facilitate lipid accumulation, augment immune responses, and induce insulin resistance, thereby exacerbating fibrosis in cases of periodontitis-associated NAFLD. The influence of oral microbiota on NAFLD <i>via</i> the \"oral-gut-liver\" axis is gaining recognition, offering a novel perspective for NAFLD management through microbial imbalance correction. This review endeavors to encapsulate the intricate roles of oral bacteria in NAFLD and explore underlying mechanisms, emphasizing microbial control strategies as a viable therapeutic avenue for NAFLD.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China. 量化肝细胞癌的自然生长率：中国西南地区的真实世界回顾性研究。
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.800
Li Tu, Hong Xie, Qi Li, Ping-Gui Lei, Pei-Ling Zhao, Fan Yang, Chi Gong, Yuan-Lin Yao, Shi Zhou
{"title":"Quantifying the natural growth rate of hepatocellular carcinoma: A real-world retrospective study in southwestern China.","authors":"Li Tu, Hong Xie, Qi Li, Ping-Gui Lei, Pei-Ling Zhao, Fan Yang, Chi Gong, Yuan-Lin Yao, Shi Zhou","doi":"10.4254/wjh.v16.i5.800","DOIUrl":"10.4254/wjh.v16.i5.800","url":null,"abstract":"<p><strong>Background: </strong>In recent years, approximately half of the newly diagnosed cases and mortalities attributed to hepatocellular carcinoma (HCC) have been reported in China. Despite the high incidence of HCC, there remains a paucity of data regarding the natural growth pattern and the determination of optimal surveillance intervals specific to the Chinese population.</p><p><strong>Aim: </strong>To quantify the natural tumor growth pattern of HCC in regional China.</p><p><strong>Methods: </strong>A retrospective analysis was performed on patients from a single institution in Southwest China who had undergone two or more serial dynamic computed tomography or magnetic resonance imaging scans between 2014 and 2020, without having received any anti-cancer therapy. Tumor growth was assessed using tumor volume doubling time (TVDT) and tumor growth rate (TGR), with volumes measured manually by experienced radiologists. Simple univariate linear regression and descriptive analysis were applied to explore associations between growth rates and clinical factors.</p><p><strong>Results: </strong>This study identifies the median TVDT for HCC as 163.4 d, interquartile range (IQR) 72.1 to 302.3 d, with a daily TGR of 0.42% (IQR 0.206%-0.97%). HCC growth patterns reveal that about one-third of tumors grow indolently with TVDT exceeding 270 d, another one-third of tumors exhibit rapid growth with TVDT under 90 d, and the remaining tumors show intermediate growth rates, with TVDT ranging between 3 to 9 months.</p><p><strong>Conclusion: </strong>The identified TGRs support biannual surveillance and follow-up for HCC patients in certain regions of China. Given the observed heterogeneity in HCC growth, further investigation is warranted.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet? 肝细胞癌的纳米革命：多学科奥德赛--我们成功了吗？
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.684
Howard D Lee, Li-Yun Yuan
{"title":"Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?","authors":"Howard D Lee, Li-Yun Yuan","doi":"10.4254/wjh.v16.i5.684","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.684","url":null,"abstract":"In this editorial we comment on the review by Zhou et al reviewing the landscape of nanomedicine in the treatment of hepatocellular carcinoma (HCC). We focus on the immense potential of nanotechnology, particularly ligand-receptor mediated nanotherapy, in revolutionizing the treatment landscape of HCC. Despite advancements in multidisciplinary treatment, HCC remains a significant global health challenge. Ligand-mediated nanotherapy offers the opportunity for precise drug delivery to tumor sites, targeting specific receptors overexpressed in HCC cells, thereby enhancing efficacy and minimizing side effects. Overcoming drug resistance and aggressive tumor biology is facilitated by nanomedicine, bypassing traditional hurdles encountered in chemotherapy. Examples include targeting glypican-3, asialoglycoprotein, transferrin receptor or folic acid receptors, capitalizing on their over-expression in tumor cells. The ability for multi-receptor targeting through dual-ligand nanoparticle modification holds the prospect of further enhancement in specificity and efficacy of directed therapy. However, challenges including immune responses, reproducibility in nanoparticle synthesis, and production scalability remain. Future directions involve refining targeting strategies, improving drug release mechanisms, and streamlining production processes to enable personalized and multifunctional nanotherapies. Overall, the integration of nanotherapy in HCC treatment holds immense promise, but continued partnership and effort are needed in offering hope for more effective, precise, and accessible clinical care in the management of HCC.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study 急性慢性肝病的特征：多中心前瞻性队列研究
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.809
Yuan-Yao Zhang, Sen Luo, Hai Li, Shu-Ning Sun, Xian-Bo Wang, Xin Zheng, Yan Huang, Bei-Ling Li, Yan-Hang Gao, Zhiping Qian, Feng Liu, Xiao-Bo Lu, Jun-Ping Liu, Hao-Tang Ren, Yu-Bao Zheng, Hua-Dong Yan, Guo-Hong Deng, Liang Qiao, Yan Zhang, W. Gu, Xiao-Mei Xiang, Yi Zhou, Yi-Xin Hou, Qun Zhang, Yan Xiong, Cong-cong Zou, Jun Chen, Ze-bing Huang, Xiuhua Jiang, Ting-Ting Qi, Yuan-Yuan Chen, Na Gao, Chun-Yan Liu, Wei Yuan, Xue Mei, Jing Li, Tao Li, Rong-Jiong Zheng, Xin-Yi Zhou, Jun Zhao, Zhong-Ji Meng
{"title":"Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study","authors":"Yuan-Yao Zhang, Sen Luo, Hai Li, Shu-Ning Sun, Xian-Bo Wang, Xin Zheng, Yan Huang, Bei-Ling Li, Yan-Hang Gao, Zhiping Qian, Feng Liu, Xiao-Bo Lu, Jun-Ping Liu, Hao-Tang Ren, Yu-Bao Zheng, Hua-Dong Yan, Guo-Hong Deng, Liang Qiao, Yan Zhang, W. Gu, Xiao-Mei Xiang, Yi Zhou, Yi-Xin Hou, Qun Zhang, Yan Xiong, Cong-cong Zou, Jun Chen, Ze-bing Huang, Xiuhua Jiang, Ting-Ting Qi, Yuan-Yuan Chen, Na Gao, Chun-Yan Liu, Wei Yuan, Xue Mei, Jing Li, Tao Li, Rong-Jiong Zheng, Xin-Yi Zhou, Jun Zhao, Zhong-Ji Meng","doi":"10.4254/wjh.v16.i5.809","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.809","url":null,"abstract":"BACKGROUND\u0000 Acute-on-chronic liver disease (AoCLD) accounts for the majority of patients hospitalized in the Department of Hepatology or Infectious Diseases.\u0000 AIM\u0000 To explore the characterization of AoCLD to provide theoretical guidance for the accurate diagnosis and prognosis of AoCLD.\u0000 METHODS\u0000 Patients with AoCLD from the Chinese Acute-on-Chronic Liver Failure (ACLF) study cohort were included in this study. The clinical characteristics and outcomes, and the 90-d survival rate associated with each clinical type of AoCLD were analyzed, using the Kaplan-Meier method and the log-rank test.\u0000 RESULTS\u0000 A total of 3375 patients with AoCLD were enrolled, including 1679 (49.7%) patients with liver cirrhosis acute decompensation (LC-AD), 850 (25.2%) patients with ACLF, 577 (17.1%) patients with chronic hepatitis acute exacerbation (CHAE), and 269 (8.0%) patients with liver cirrhosis active phase (LC-A). The most common cause of chronic liver disease (CLD) was HBV infection (71.4%). The most common precipitants of AoCLD was bacterial infection (22.8%). The 90-d mortality rates of each clinical subtype of AoCLD were 43.4% (232/535) for type-C ACLF, 36.0% (36/100) for type-B ACLF, 27.0% (58/215) for type-A ACLF, 9.0% (151/1679) for LC-AD, 3.0% (8/269) for LC-A, and 1.2% (7/577) for CHAE.\u0000 CONCLUSION\u0000 HBV infection is the main cause of CLD, and bacterial infection is the main precipitant of AoCLD. The most common clinical type of AoCLD is LC-AD. Early diagnosis and timely intervention are needed to reduce the mortality of patients with LC-AD or ACLF.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbiota treatment of functional constipation: Current status and future prospects 功能性便秘的微生物群治疗：现状与前景
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.776
Yan Li, Xiao-Han Zhang, Zi-Kai Wang
{"title":"Microbiota treatment of functional constipation: Current status and future prospects","authors":"Yan Li, Xiao-Han Zhang, Zi-Kai Wang","doi":"10.4254/wjh.v16.i5.776","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.776","url":null,"abstract":"Functional constipation (FC) is a common disorder that is characterized by difficult stool passage, infrequent bowel movement, or both. FC is highly prevalent, recurs often, accompanies severe diseases, and affects quality of life; therefore, safe and effective therapy with long-term benefits is urgently needed. Microbiota treatment has potential value for FC treatment. Microbiota treatments include modulators such as probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT). Some probiotics and prebiotics have been adopted, and the efficacy of other microbiota modulators is being explored. FMT is considered an emerging field because of its curative effects; nevertheless, substantial work must be performed before clinical implementation.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease 输血依赖型β地中海贫血患者的肝病：代谢功能障碍相关性脂肪性肝病的新作用
IF 2.4
World Journal of Hepatology Pub Date : 2024-05-27 DOI: 10.4254/wjh.v16.i5.671
N. Fragkou, E. Vlachaki, Ioannis Goulis, E. Sinakos
{"title":"Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease","authors":"N. Fragkou, E. Vlachaki, Ioannis Goulis, E. Sinakos","doi":"10.4254/wjh.v16.i5.671","DOIUrl":"https://doi.org/10.4254/wjh.v16.i5.671","url":null,"abstract":"In this Editorial, we highlight the possible role that metabolism dysfunction-associated steatotic liver disease (MASLD) may play in the future, regarding liver disease in patients with transfusion-dependent β-thalassemia (TDBT). MASLD is characterized by excessive accumulation of fat in the liver (hepatic steatosis), in the presence of cardiometabolic factors. There is a strong correlation between the occurrence of MASLD and insulin resistance, while its increased prevalence parallels the global epidemic of diabetes mellitus (DM) and obesity. Patients with TDBT need regular transfusions for life to ensure their survival. Through these transfusions, a large amount of iron is accumulated, which causes saturation of transferrin and leads to the circulation of free iron molecules, which cause damage to vital organs (primarily the liver and myocardium). Over the past, the main mechanisms for the development of liver disease in these patients have been the toxic effect of iron on the liver and chronic hepatitis C, for which modern and effective treatments have been found, resulting in successful treatment. Additional advances in the treatment and monitoring of these patients have led to a reduction in deaths, and an increase in their life expectancy. This increased survival makes them vulnerable to the onset of diseases, which until recently were mainly related to the non-thalassemic general population, such as obesity and DM. There is insufficient data in the literature regarding the prevalence of MASLD in this population or on the risk factors for its occurrence. However, it was recently shown by a study of 45 heavily transfused patients with beta-thalassemia (Padeniya et al , BJH), that the presence of steatosis is a factor influencing the value of liver elastography and thus liver fibrosis. These findings suggest that future research in the field of liver disease in patients with TDBT should be focused on the occurrence, the risk factors, and the effect of MASLD on these patients.","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141098134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信